Eisai Co., Ltd.

This phase 2 trial tests whether the experimental drug E6742 can reduce lupus disease activity better than a placebo. About 256 adults with lupus will take either E6742 or a placebo pill for 24 weeks. The main goal is to see if more people on E6742 achieve a meaningful reduction …

This study looks at the safety of the drug Tasfygo in 60 people with advanced biliary tract cancer that has a specific gene change (FGFR2 fusion) and has gotten worse after chemotherapy. Researchers will track side effects and how well the drug works. The goal is to make sure the…

This study tracks the safety of Fycompa injection in people with epilepsy who have partial-onset seizures (age 4 and older) or primary generalized tonic-clonic seizures (age 12 and older). Researchers will record any side effects and measure drug levels in children aged 4 to 12. …

This study looks at how mild and moderate liver problems change the way the body handles a single dose of the drug tasurgratinib. Researchers will compare 18 people with stable liver impairment to healthy volunteers matched by age, weight, race, and gender. The goal is to underst…

This study is tracking 5,000 people with early Alzheimer's who are taking the drug lecanemab in regular medical practice. The goal is to see how often brain changes called ARIA occur and how doctors manage treatment when they do. Researchers will also look at infusion reactions. …